References

  1. Brugnara C, Eckardt K-U. Hematologic aspects of kidney disease. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. Brenner & Rector’s The Kidney. 10th ed. Elsevier; 2016:1875-1911.
  2. Wenger RH, Hoogewijs D. Regulated oxygen sensing by protein hydroxylation in renal erythropoietin-producing cells. Am J Physiol Renal Physiol. 2010;298(6):F1287-F1296.
  3. O’Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectr. 2008;21(1):12-19.
  4. Liu Q, Davidoff O, Niss K, Haase VH. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012;122(12):4635-4644.
  5. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55(6):667-674.
  6. Gupta J, Mitra N, Kanetsky PA, et al; CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012;7(12):1938-1946.
  7. Novak JE, Yee J. Anemia in chronic kidney disease. In: Coffman TM, Falk RJ, Molitoris BA, Neilson EG, Schrier RW, eds. Schrier’s Diseases of the Kidney. 9th ed. Lippincott Williams & Wilkins; 2013:2238-2256.
  8. Lopez A, Cacoub P, Macdougall IC, Peyrin-Biroulet L. Iron deficiency anaemia. Lancet. 2016;387(10021):907-916.
  9. Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1(suppl 1):S4-S8.
  10. Hörl WH, Cavill I, Macdougall IC, Schaefer RM, Sunder-Plassmann G. How to diagnose and correct iron deficiency during r-huEPO therapy—a consensus report. Nephrol Dial Transplant. 1996;11(2):246-250.
  11. Pan X, Suzuki N, Hirano I, Yamazaki S, Minegishi N, Yamamoto M. Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PLoS One. 2011;6(10):e25839.
  12. Donnelly S. Why is erythropoietin made in the kidney? The kidney functions as a critmeter. Am J Kidney Dis. 2001;38(2):415-425.
  13. Singh P, McDonough AA, Thomson SC. Metabolic basis of solute transport. In: Skorecki K, Chertow GM, Marsden PA, Taal MW, Yu ASL, eds. Brenner & Rector’s The Kidney. 10th ed. Elsevier; 2016:122-143.
  14. Souma T, Yamazaki S, Moriguchi T, et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J Am Soc Nephrol. 2013;24(10):1599-1616.
  15. Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol. 2015;11(7):394-410.
  16. Halperin ML, Cheema-Dhadli S, Lin SH, Kamel KS. Properties permitting the renal cortex to be the oxygen sensor for the release of erythropoietin: clinical implications. Clin J Am Soc Nephrol. 2006;1(5):1049-1053.
  17. Lassen NA, Munck O, Thaysen JH. Oxygen consumption and sodium reabsorption in the kidney. Acta Physiol Scand. 1961;51:371-384.
  18. Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187-199.
  19. Prchal JT. Delivery on demand—a new era of gene therapy? N Engl J Med. 2003;348(13):1282-1283.
  20. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, Peyssonnaux C. HIF-2α, but not HIF-1α, promotes iron absorption in mice. J Clin Invest. 2009;119(5):1159-1166.
  21. Rudnicki M, Perco P, Enrich J, et al. Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease. Lab Invest. 2009;89(3):337-346.
  22. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl. 2012;2(4):279-335.
  23. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30(2):187-196.
  24. National Institutes of Health. Your Guide to Anemia. NIH Publication No. 11-7629. US Department of Health and Human Services, National Institute of Health. September 2011.
  25. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74(7):867-872.
  26. Hare GMT. Anaemia and the brain. Curr Opin Anaesthesiol. 2004;17(5):363-369.
  27. Kamata T, Hishida A, Takita T, et al. Morphologic abnormalities in the brain of chronically hemodialyzed patients without cerebrovascular disease. Am J Nephrol. 2000;20(1):27-31.
  28. Ronco C, Di Lullo L. Cardiorenal syndrome in Western countries: epidemiology, diagnosis and management approaches. Kidney Dis (Basel). 2016;2(4):151-163.
  29. Walle AJ, Wong GY, Clemons GK, Garcia JF, Niedermayer W. Erythropoietin-hematocrit feedback circuit in the anemia of end-stage renal disease. Kidney Int. 1987;31(5):1205-1209.
  30. Yamazaki S, Souma T, Hirano I, et al. A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat Commun. 2013;4:1950.
  31. Solak Y, Cetiner M, Siriopol D, et al. Novel masters of erythropoiesis: hypoxia inducible factors and recent advances in anemia of renal disease. Blood Purif. 2016;42(2):160-167.